Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing | Synapse
June 1, 2023Open Access
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Key Points
Key points are not available for this paper at this time.
Abstract
Amgen, Celgene/Bristol Myers Squibb, Multiple Myeloma Research Foundation.